sorbitol has been researched along with Weight Loss in 13 studies
D-glucitol : The D-enantiomer of glucitol (also known as D-sorbitol).
Weight Loss: Decrease in existing BODY WEIGHT.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study aimed to assess the effect of luseogliflozin on liver fat deposition and compare luseogliflozin to metformin in type 2 diabetes (T2D) patients with non-alcoholic fatty liver disease (NAFLD)." | 9.27 | Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective randomized controlled pilot study. ( Fushimi, N; Hachiya, H; Ito, S; Kawai, H; Kawai, M; Mori, A; Ohashi, N; Shibuya, T; Yoshida, Y, 2018) |
| "This study aimed to assess the effect of luseogliflozin on liver fat deposition and compare luseogliflozin to metformin in type 2 diabetes (T2D) patients with non-alcoholic fatty liver disease (NAFLD)." | 5.27 | Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective randomized controlled pilot study. ( Fushimi, N; Hachiya, H; Ito, S; Kawai, H; Kawai, M; Mori, A; Ohashi, N; Shibuya, T; Yoshida, Y, 2018) |
| "This dose-response analysis evaluated change in body weight following 24 weeks with four once-daily and twice-daily licogliflozin doses (2." | 2.94 | Licogliflozin, a Novel SGLT1 and 2 Inhibitor: Body Weight Effects in a Randomized Trial in Adults with Overweight or Obesity. ( Bays, HE; Keefe, D; Kozlovski, P; Proot, P; Shao, Q, 2020) |
| "Moderately obese Japanese type 2 diabetes patients, treated with luseogliflozin for a year, were observed prospectively and evaluated for body composition changes." | 2.90 | Sodium-glucose cotransporter 2 inhibitor-induced changes in body composition and simultaneous changes in metabolic profile: 52-week prospective LIGHT (Luseogliflozin: the Components of Weight Loss in Japanese Patients with Type 2 Diabetes Mellitus) Study. ( Fukuda, M; Sasaki, T; Sugawara, M, 2019) |
| " There were no significant differences in the incidences of adverse events among groups." | 2.79 | Efficacy and safety of luseogliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, placebo-controlled, phase II study. ( Fukatsu, A; Sakai, S; Samukawa, Y; Sasaki, T; Seino, Y, 2014) |
| " Safety assessments included adverse events (AEs), clinical laboratory tests, and vital signs." | 2.79 | Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study. ( Fukatsu, A; Sakai, S; Samukawa, Y; Sasaki, T; Seino, Y; Ubukata, M, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 2 (15.38) | 29.6817 |
| 2010's | 8 (61.54) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Bays, HE | 1 |
| Kozlovski, P | 1 |
| Shao, Q | 1 |
| Proot, P | 1 |
| Keefe, D | 1 |
| Seino, Y | 5 |
| Yabe, D | 1 |
| Sasaki, T | 6 |
| Fukatsu, A | 5 |
| Imazeki, H | 1 |
| Ochiai, H | 1 |
| Sakai, S | 5 |
| Shibuya, T | 1 |
| Fushimi, N | 1 |
| Kawai, M | 1 |
| Yoshida, Y | 1 |
| Hachiya, H | 1 |
| Ito, S | 1 |
| Kawai, H | 1 |
| Ohashi, N | 1 |
| Mori, A | 1 |
| Sugawara, M | 1 |
| Fukuda, M | 1 |
| Samukawa, Y | 4 |
| Ubukata, M | 3 |
| Kaku, K | 1 |
| Inagaki, N | 1 |
| Haneda, M | 1 |
| Shyangdan, DS | 1 |
| Uthman, OA | 1 |
| Waugh, N | 1 |
| Bauditz, J | 1 |
| Norman, K | 1 |
| Biering, H | 1 |
| Lochs, H | 1 |
| Pirlich, M | 1 |
| Saussele, T | 1 |
| Jiang, ZM | 1 |
| Zhang, SY | 1 |
| Wang, XR | 1 |
| Yang, NF | 1 |
| Zhu, Y | 1 |
| Wilmore, D | 1 |
| Berneis, K | 1 |
| Iseli-Schaub, J | 1 |
| Garbani, E | 1 |
| Meier, R | 1 |
| Kiss, D | 1 |
1 review available for sorbitol and Weight Loss
| Article | Year |
|---|---|
SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis.
Topics: Bayes Theorem; Benzhydryl Compounds; Blood Pressure; Canagliflozin; Diabetes Mellitus, Type 2; Drug | 2016 |
10 trials available for sorbitol and Weight Loss
| Article | Year |
|---|---|
Licogliflozin, a Novel SGLT1 and 2 Inhibitor: Body Weight Effects in a Randomized Trial in Adults with Overweight or Obesity.
Topics: Adolescent; Adult; Aged; Anhydrides; Body Weight; Double-Blind Method; Female; Humans; Male; Middle | 2020 |
Sodium-glucose cotransporter-2 inhibitor luseogliflozin added to glucagon-like peptide 1 receptor agonist liraglutide improves glycemic control with bodyweight and fat mass reductions in Japanese patients with type 2 diabetes: A 52-week, open-label, singl
Topics: Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon- | 2018 |
Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective randomized controlled pilot study.
Topics: Adiposity; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans | 2018 |
Sodium-glucose cotransporter 2 inhibitor-induced changes in body composition and simultaneous changes in metabolic profile: 52-week prospective LIGHT (Luseogliflozin: the Components of Weight Loss in Japanese Patients with Type 2 Diabetes Mellitus) Study.
Topics: Asian People; Blood Glucose; Body Composition; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycem | 2019 |
Efficacy and safety of luseogliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, placebo-controlled, phase II study.
Topics: Adult; Aged; Asian People; Biomarkers; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; | 2014 |
Dose-finding study of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, double-blind, placebo-controlled, phase II study.
Topics: Adult; Aged; Asian People; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relat | 2014 |
Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; | 2014 |
Fifty-two-week long-term clinical study of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise.
Topics: Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hy | 2015 |
A comparison of medium-chain and long-chain triglycerides in surgical patients.
Topics: Drug Combinations; Fat Emulsions, Intravenous; Female; Humans; Insulin; Ketone Bodies; Male; Middle | 1993 |
Effects of intradialytic parenteral nutrition in chronic haemodialysis patients with malnutrition: a pilot study.
Topics: Aged; Aged, 80 and over; Amino Acids; Body Mass Index; Drug Combinations; Eating; Fat Emulsions, Int | 1999 |
2 other studies available for sorbitol and Weight Loss
| Article | Year |
|---|---|
Severe weight loss caused by chewing gum.
Topics: Adult; Cathartics; Chewing Gum; Diarrhea; Female; Humans; Male; Middle Aged; Sorbitol; Sweetening Ag | 2008 |
[Diarrhea. Diarrhea and loss of weight from use of chewing gum].
Topics: Chewing Gum; Diarrhea; Humans; Sorbitol; Sweetening Agents; Weight Loss | 2008 |